Key Takeaways
- • Artificial intelligence and policy uncertainty are the top concerns for healthcare dealmakers, according to attendees at McDermott Will & Schulte's recent annual New York private-equity healthcare conference.
- • McDermott Chairman Ira Coleman said the policy landscape "may be changing in a pretty profound way," urging investors and operators to plan around it.
- • Buyers are increasingly demanding proven market resilience and insulation from government changes amid an uneven market recovery.
Summary
Artificial intelligence and policy uncertainty dominated discussion among healthcare dealmakers at law firm McDermott Will & Schulte's recent annual New York private-equity healthcare conference, according to attendees reported by Dow Jones.
McDermott Chairman Ira Coleman told the conference that the policy environment "may be changing in a pretty profound way," and said it is a variable that every investor and operator in the room needs to plan around or at least take into consideration.
The discussion reflects a broader shift in buyer expectations. Against an uneven market recovery, buyers are increasingly seeking assets with proven market resilience and insulation from government changes, according to the report. The source material available for this story is limited, and it does not provide deal values, specific policy details, or named transactions.
McDermott Chairman Ira Coleman told the conference that the policy environment "may be changing in a pretty profound way," and said it is a variable that every investor and operator in the room needs to plan around or at least take into consideration.
The discussion reflects a broader shift in buyer expectations. Against an uneven market recovery, buyers are increasingly seeking assets with proven market resilience and insulation from government changes, according to the report. The source material available for this story is limited, and it does not provide deal values, specific policy details, or named transactions.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.